Linking therapeutically active molecules to specific antibodies can help to pilot them to their designated targets and minimize side effects -- especially when treating tumors. Scientists have now described novel conjugates made from antibodies and a kinesin spindle protein inhibitor. Changing the linker between the two components allows for tuning the activity of this cytostatic drug, which is effective against a broad palette of cancers.
from Top Technology News -- ScienceDaily https://ift.tt/2yHugYJ
via IFTTT
Technology and Professional News
IFTTT
Top Technology News -- ScienceDaily
Flexible, stable and potent against cancer
Next
« Prev Post
« Prev Post
Previous
Next Post »
Next Post »
Subscribe to:
Post Comments (Atom)
EmoticonEmoticon